Alec Machiels
About Alec Machiels
Independent director of Apellis since 2009; age 52 as of April 2025. Founding Managing Partner at CoLift LLC (2019–present); prior Partner at Pegasus Capital Advisors (2006–2019; joined 2002). Education: MBA Harvard Business School; License in Law (KU Leuven); MA International Economics (Konstanz University). Designated by the Board as an “audit committee financial expert.”
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Pegasus Capital Advisors, L.P. | Partner | 2006–2019 (joined 2002) | Private equity leadership; board experience across public/private companies (unspecified) |
| Potentia Pharmaceuticals, Inc. | Co‑Founder & CEO | 2001–2002 | Potentia was predecessor to Apellis; assets acquired by Apellis in Sep 2015 |
| Revon | Co‑Founder | 2013–2019 | Healthcare software venture |
| Goldman Sachs | Financial Analyst (FS Group London; Private Equity Group New York) | 1996–1999 | Finance/transactions experience |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| CoLift, LLC | Founding Managing Partner | 2019–present | Private equity platform |
| Other boards | Director (previously) | Not specified | Proxy notes prior service on several public/private boards (names not disclosed) |
Board Governance
- Board classification: Class II director; nominated for re‑election at the 2025 Annual Meeting (term to 2028 if elected) .
- Committees: Audit (Chair), Compensation (Member), Compliance (Member) .
- Audit committee financial expert designation; committee independence affirmed under Nasdaq/SEC rules .
- Independence: Board determined all non‑employee directors, including Machiels, are independent (Feb–Apr 2025 review) .
- Attendance: Board met 7 times in 2024; each director attended ≥75% of board and committee meetings served; independent directors held 5 executive sessions in 2024 .
- Board leadership: Independent Chair (Gerald Chan); no Lead Independent Director given Chair independence .
Fixed Compensation
- Director fee structure (2024 program—unchanged for 2025): Board member $50,000; Audit member $12,500 + Audit Chair add’l $12,500; Compensation member $10,000; Compliance member $7,500; Nominating & Governance member $7,500; board chair add’l $33,750 (not applicable to Machiels) .
- 2024 amounts earned by Machiels:
| Component | Amount ($) |
|---|---|
| Board retainer | 50,000 |
| Audit Committee – member | 12,500 |
| Audit Committee – chair add’l | 12,500 |
| Compensation Committee – member | 10,000 |
| Compliance Committee – member | 7,500 |
| Cash fees total | 92,500 |
| Option awards (grant-date fair value) | 199,973 |
| RSU awards (grant-date fair value) | 199,992 |
| 2024 total compensation | 492,465 |
Performance Compensation
- Annual non‑employee director equity program:
- Jan 2024 grants to each eligible director: Options 5,748; RSUs 3,341; options vest in four quarterly installments within the year (and next Jan 1) and have a 7‑year term; RSUs vest at 1‑year anniversary; change in control vests awards in full .
- Jan 2025 grants to each eligible director: Options 11,199; RSUs 6,267; same vesting terms; no program changes for 2025 .
| Grant Date | Instrument | Shares/Units | Vesting | Term/Notes |
|---|---|---|---|---|
| Jan 1, 2024 | Stock Options | 5,748 | 4 equal quarterly installments in 2024 and Jan 1, 2025; service‑based | 7‑year term; exercise price = FMV at grant |
| Jan 1, 2024 | RSUs | 3,341 | 100% on first anniversary (deferral optional) | Full acceleration on change in control |
| Jan 1, 2025 | Stock Options | 11,199 | 4 equal quarterly installments in 2025 and Jan 1, 2026; service‑based | 7‑year term; exercise price = FMV at grant |
| Jan 1, 2025 | RSUs | 6,267 | 100% on first anniversary (deferral optional) | Full acceleration on change in control |
- Outstanding awards (as of Dec 31, 2024): Options 216,417; RSUs 6,606 .
Other Directorships & Interlocks
- Prior board service: “several public and private companies” (not named) .
- Voting proxy over CEO‑related trust shares: Holds voting proxy for 234,411 shares in The Francois‑DuBois Educational Trust (also listed within CEO’s beneficial ownership), creating an interlock in voting authority with management holdings .
- Committee interlocks: None disclosed; compensation committee interlocks section indicates no officer/committee cross‑appointments with external entities .
Expertise & Qualifications
- Financial, legal, and investment background; board experience across public/private companies .
- Education: MBA (Harvard), License in Law (KU Leuven), MA International Economics (Konstanz) .
- Audit committee financial expert designation; financial sophistication per Nasdaq rules .
Equity Ownership
- Beneficial ownership (as of March 31, 2025): 1,229,732 shares (≈1.0% of outstanding); includes:
- 598,566 shares directly;
- 250,000 shares held by Bauhaus 1, LLC (wholly owned by a trust of which Machiels is investment trustee);
- 161,950 shares held by affiliates;
- 234,411 shares in The Francois‑DuBois Educational Trust (voting proxy held by Machiels);
- 219,216 shares issuable upon exercise of options exercisable within 60 days .
- Stock ownership guidelines: Directors must hold ≥3x annual cash retainer; all directors met guidelines at implementation and as of Dec 31, 2024 .
| Holder/Source | Shares |
|---|---|
| Direct (Machiels) | 598,566 |
| Bauhaus 1, LLC (trust where Machiels is investment trustee) | 250,000 |
| Affiliates | 161,950 |
| Francois‑DuBois Educational Trust (voting proxy held by Machiels) | 234,411 |
| Options exercisable ≤60 days | 219,216 |
| Total beneficial | 1,229,732 (≈1.0%) |
Say‑on‑Pay & Shareholder Feedback
- 2024 say‑on‑pay support: 89.9% approval of executive compensation .
- 2023 say‑on‑pay support: >93% approval .
Governance Assessment
-
Strengths
- Long‑tenured independent director with deep finance/investment background; designated audit committee financial expert; chairs audit committee overseeing financial reporting, risk, compliance, related‑party transactions, and cybersecurity .
- Independence affirmed; board has independent Chair; regular executive sessions; attendance met board standard (≥75%) .
- Ownership alignment: meaningful beneficial stake; directors meet stock ownership guidelines .
-
Watch items / RED FLAGS
- Pledging of Apellis stock: Audit Committee permitted Machiels in 2024 to pledge Company securities as part of a broader collateral package for an extension of credit—pledging is generally discouraged in governance best practice due to potential forced sale risk; monitor scope and any updates to pledging exceptions .
- Voting proxy interlock: Machiels holds voting proxy over 234,411 shares in a trust associated with CEO’s beneficial ownership, which could create perceived influence over management‑associated votes; monitor for any related‑party considerations or recusal practices .
- Single‑trigger vesting on change in control for director equity awards (accelerates vesting), which can be viewed as shareholder‑unfriendly by some investors; this is the standard under the director program .
-
Compensation Committee analysis
- Composition: O’Brien (Chair), Fonteyne, Machiels; Walbert added in March 2025; met six times in 2024 .
- Consultant: Pay Governance serves as independent compensation consultant; committee assessed independence and found no conflicts, though management also engaged them for broader employee compensation work at committee direction .
- Director pay: Mixed cash + equity; no meeting fees; annual grants in options and RSUs; program unchanged for 2025 .
-
Related‑party transactions
- Company maintains formal RPT policy with audit committee review; no director‑specific RPTs disclosed beyond voting proxy note; indemnification agreements standard for directors .
Overall, Machiels brings strong financial oversight as Audit Chair and significant ownership alignment. The 2024 pledge approval and voting proxy over CEO‑related trust shares are notable governance sensitivities; continued transparency and adherence to independence and RPT policies mitigate risk if monitored appropriately.